The mRNA level of PFK , a key glycolysis-related gene, was significantly decreased (fasting state) and increased (feeding state) in the muscle, but was comparable in the liver (Fig
Standard GLP-1 eligibility thresholds - based on the FDA-approved drug labeling for Wegovy and Zepbound, which guides how clinicians think about the category - generally include a BMI of 30 or higher (obese), or a BMI of 27 or higher with at least one weight-related comorbidity such as high blood pressure, high cholesterol, or type 2 diabetes
Peer-reviewed preclinical data synthesis
Track Symptoms Log dose times, side effects, weight, appetite, blood sugar, and misses using a journal or app
When to Seek Medical Advice About Feeling Cold Whilst mild cold sensitivity associated with weight loss is generally not concerning, certain circumstances warrant prompt medical evaluation

Patient Selection and Assessment Criteria for patient eligibility, medical history and contraindications According to the package insert: Wegovy (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management: YES: adults with an initial body mass index (BMI) of 30 kg/m2 (obesity) or 27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity) NO: Patients with a personal or family history of MTC Patients with MEN 2 Patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in semaglutide WARNING & PRECAUTIONS: Risk of the following: Thyroid C-Cell Tumors Acute Pancreatitis Acute Gallbladder Disease Hypoglycemia Acute Kidney Injury Hypersensitivity Reactions Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Heart Rate Increase Suicidal Behavior and Ideation ADDITIONAL Patients should be warned about the following: History of type 1 diabetes or diabetic ketoacidosis, as semaglutide is not indicated for these conditions
